Suchergebnisse - "Barclay, Stephen"

PubPharm (357)

51

Changes in mortality patterns and place of death during the COVID-19 pandemic : A descriptive analysis of mortality data across four nations

enthalten in: Palliative medicine | 2021

von O'Donnell, S. | Bone, A. | Finucane, A. | +5

52

Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection

enthalten in: JHEP reports : innovation in hepatology | 2021

von Innes, H. | Jepsen, P. | McDonald, S. | +16

53

Communication of poor prognosis between secondary and primary care : protocol for a systematic review with narrative synthesis

enthalten in: BMJ open | 2021

von Pocock, L. | Purdy, S. | Barclay, S. | +2

54

Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

enthalten in: bioRxiv.org | 2021

von Cooke, G. | Pett, S. | McCabe, L. | +22

55

Community end-of-life care during the COVID-19 pandemic: Initial findings of a UK primary care survey

enthalten in: bioRxiv.org | 2021

von Mitchell, S. | Oliver, P. | Gardiner, C. | +6

56

Unwelcome memento mori or best clinical practice? Community end-of-life anticipatory medication prescribing practice: a mixed methods observational study

enthalten in: bioRxiv.org | 2021

von Bowers, B. | Pollock, K. | Barclay, S.

57

Hospice at Home services in England : a national survey

enthalten in: BMJ supportive & palliative care | 2021

von Rees-Roberts, M. | Williams, P. | Hashem, F. | +9

58

The association between deprivation and the incidence and survival of patients with hepatocellular carcinoma in the West of Scotland

enthalten in: Expert review of gastroenterology & hepatology | 2021

von Curran, C. | Stanley, A. | Barclay, S. | +2

59

Timely community palliative and end-of-life care : a realist synthesis

enthalten in: BMJ supportive & palliative care | 2021

von Petrova, M. | Wong, G. | Kuhn, I. | +2

60

Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials

enthalten in: Journal of viral hepatitis | 2021

von Gane, E. | de Ledinghen, V. | Dylla, D. | +7